This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acadia Healthcare (ACHC) Shares Down 9% Despite Q1 Earnings Beat
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q1 results aided by improved revenue per patient day, partly offset by escalating costs. It continues to expect 2024 adjusted EPS within $3.40-$3.70.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Centene and Humana
by Zacks Equity Research
UnitedHealth, The Cigna, Centene and Humana have been highlighted in this Industry Outlook article.
4 HMO Stocks to Watch Amid Persistent Industry Challenges
by Debasmita Chatterjee
The Medical-HMO industry continues to witness an expanding customer base resulting from contract wins. However, high technology expenses and a shortage of medical personnel are a concern. UNH, CI, CNC and HUM are likely to navigate industry storms.
Compared to Estimates, Cigna (CI) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Cigna (CI) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cigna (CI) Q1 Earnings Beat on Client Wins in Evernorth Unit
by Zacks Equity Research
Cigna's (CI) Q1 results reflect strong organic growth in the Evernorth Health Services unit. It expects adjusted EPS of at least $28.40 for 2024, up from the earlier guidance of at least $28.25.
Cigna (CI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 4.86% and 1.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Cigna Group (CI)
by Zacks Equity Research
Cigna Group (CI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analyzing How You Should Play Cigna (CI) Ahead of Q1 Earnings
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect expanding commercial middle market memberships and growth in Cigna Healthcare profits.
Why Cigna (CI) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Unveiling Cigna (CI) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Cigna (CI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
The Zacks Analyst Blog Highlights Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare
by Zacks Equity Research
Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare are part of the Zacks top Analyst Blog.
Cigna (CI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cigna (CI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stay Ahead With 4 Healthcare Stocks Poised for Q1 Earnings Beat
by Kaibalya Pravo Dey
Growing patient volumes, advancements in technology, admissions, premium rate hikes and other factors are likely to have benefited healthcare players during Q1. Companies like CI, HCA, AVTR and THC can outperform.
Cigna (CI) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Cigna (CI) stood at $352.65, denoting a -0.15% change from the preceding trading day.
Here's Why Cigna (CI) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why the Market Dipped But Cigna (CI) Gained Today
by Zacks Equity Research
Cigna (CI) closed at $348.78 in the latest trading session, marking a +0.78% move from the prior day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
UnitedHealth Group (UNH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 4.22% and 0.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Stock Moves -0.92%: What You Should Know
by Zacks Equity Research
Cigna (CI) reachead $349.84 at the closing of the latest trading day, reflecting a -0.92% change compared to its last close.
Acadia Healthcare (ACHC) Opens Facility to Address Mental Health
by Zacks Equity Research
Acadia Healthcare (ACHC) inaugurates an acute care hospital in Mesa, AZ, to cater to patients struggling with addiction and mental health issues in the area.
Here's Why Cigna (CI) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Brookdale Senior (BKD) Sees Y/Y Increase in Q1 Occupancy Levels
by Zacks Equity Research
Brookdale Senior (BKD) witnesses 29 straight months of year-over-year increases in weighted average occupancy level.
CI vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?